|
Study
|
Objective
|
Contact
|
|
A Phase 2 Randomized Open-Label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
The purpose of this study is to help test an investigational study drug called tivantinib or ARQ 197 in combination with erlotinib (Tarceva®)
|
Principal Investigator(s):
Paul J. Hesketh, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Julia C. Roache.
|
|
A Pilot Study: A Randomized, Controlled Trial Comparing Medical Thoracoscopy With Talc Pleurodesis And Chest Tube Placement vs. Medical Thoracoscopy With Talc Pleurodesis, Chest Tube Placement And Simultaneous Pleural Catheter Placement For The Treatment Of Symptomatic Malignant Pleural Effusion
|
The purpose of this study is to evaluate two available methods for alleviating the symptoms from a large pleural effusion related to cancer.
|
Principal Investigator(s):
Carla R. Lamb, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Maria Wertz.
|
|
Circulating Tumor Cells in Patients with Primary Carcinoma of the Lung and Patients who are Candidates for Pulmonary Metastasectomy for Metastatic Colorectal, Breast, and Prostate Cancer
|
Why is this study being done? To determine if tumor cells can be isolated and treated from peripheral blood and blood from the part of lung that is being removed for the treatment of the tumor.
|
Principal Investigator(s):
Christina Williamson, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Frances A. Babcock.
|
|
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
To collect, process, store, and distribute tumor-related and normal biospecimens from advanced stage lung cancer patients in support of ALCMI-approved research projects.
To maintain a centralized, computerized database of all specimens with uniform and complete demographic, pathologic, and clinical information.
To facilitate integration of molecular assays and other laboratory studies with demographic data and clinical outcomes.
To obtain funding from National Institutes of Health based on the use of the biorepository to enable or discovery of novel genes and proteins that are being investigated by the academic contributors.
|
Principal Investigator(s):
Paul J. Hesketh, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Kathleen (Kai) Sherman.
|
|
ECOG E1505: A Phase III Randomized Trial Of Adjuvant Chemotherapy With Or Without Bevacizumab For Patients With Completely Resected Stage IB(>= 4cm)-IIIA Non-Small Cell Lung Cancer (NSCLC)
|
This research is being done because even with surgery, there is a risk that the lung cancer may recur or spread. Treatment with chemotherapy after surgery has been shown to reduce (but not eliminate) the risk of recurrence or spread. This study is being done to determine whether the addition of a new agent (bevacizumab) to the chemotherapy regimen will further improve the chances of remaining free of lung cancer recurrence or spread. We will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on you and your lung cancer to see which is better at preventing the cancer from coming back. Bevacizumab is investigational, which means it has not been approved by the FDA for use in this cancer.
|
Principal Investigator(s):
Paul J. Hesketh, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Julia C. Roache.
|
|
Impact Of Aggressive Versus Standard Drainage Regimen Using A Long Term Indwelling Pleural Catheter On The Incidence Of Auto-Pleurodesis In Patients With Malignant Pleural Effusions (The ASAP Study)
|
The purpose of this research study is to compare the experiences of patients who drain fluid collections or malignant pleural effusions (MPEs) from around their lung(s) in a more aggressive or frequent manner (i.e., everyday) using a PleuRx® catheter and 1-liter collection bottle and those patients who drain this fluid in a standard or less frequent manner (i.e., every other day) using a PleuRx® catheter and a 600cc collection bottle.
|
Principal Investigator(s):
Carla R. Lamb, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Donna R. Spencer,
Maria Wertz.
|
|
LUX-Lung 8: A Randomized, Open-Label Phase III Trial of Afatinib Versus Erlotinib in Patients with Advanced Squamous Cell Carcinoma of the Lung as Second-Line Therapy Following First-Line Platinum-Based Chemotherapy
|
The purpose of this research study is to:
Test the effectiveness of the investigational study drug, afatinib, compared to erlotinib (a prescribed drug for treatment of lung cancer) as the second-line treatment (the initial treatment stopped working or the side effects were not well tolerated) for patients with advanced non-small cell squamous cell lung cancer – squamous cell type.
|
Principal Investigator(s):
Paul J. Hesketh, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Julia C. Roache.
|
|
Molecular Analysis of Cancer
|
The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA).
Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer.
|
Principal Investigator(s):
Kimberly R. Christ, PhD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Doreen L. Browne, ,CCRP,
Jane S. Nalwalk,
Linda M. Topjian.
|
|
S0709, A Phase II Selection Design Of Pharmacodynamic Separation Of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) Or OSI-774 Alone In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2) Selected By Serum Proteomics
|
The purpose of this study is to find out whether a pill, OSI-774 (erlotinib), with or without chemotherapy (carboplatin and paclitaxel) would be effective in controlling your lung cancer by either shrinking the tumor or preventing it from growing. This study will look into the effects of the planned therapy on your cancer if you have a certain level of a protein called epidermal growth factor receptor (EGFR).
|
Principal Investigator(s):
Paul J. Hesketh, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Julia C. Roache.
|
|
S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carboplatin/Paclitaxel/Bevacizumab With Or Without Concurrent Cetuximab In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
|
The purpose of this study is compare the effects, good and/or bad, of the addition of cetuximab to the common treatment of carboplatin, paclitaxel and bevacizumab to the same drugs without cetuximab on you and your lung cancer to find out which is better.
|
Principal Investigator(s):
Paul J. Hesketh, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Julia C. Roache.
|